Hydrogen Sulfide Increases the Analgesic Effects of µ- and δ-Opioid Receptors during Neuropathic Pain: Pathways Implicated

Recent studies have revealed that hydrogen sulfide (H<sub>2</sub>S) increases the analgesic actions of the δ-opioid receptor (DOR) in inflammatory pain. However, the possible improvement of the analgesia of μ-opioid receptor (MOR) and DOR agonists during neuropathic pain, through pretrea...

Full description

Saved in:
Bibliographic Details
Main Authors: Xue Bai (Author), Gerard Batallé (Author), Gianfranco Balboni (Author), Olga Pol (Author)
Format: Book
Published: MDPI AG, 2022-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_0cf3b559750a4dbd9f62b0f5a8bcf93f
042 |a dc 
100 1 0 |a Xue Bai  |e author 
700 1 0 |a Gerard Batallé  |e author 
700 1 0 |a Gianfranco Balboni  |e author 
700 1 0 |a Olga Pol  |e author 
245 0 0 |a Hydrogen Sulfide Increases the Analgesic Effects of µ- and δ-Opioid Receptors during Neuropathic Pain: Pathways Implicated 
260 |b MDPI AG,   |c 2022-07-01T00:00:00Z. 
500 |a 10.3390/antiox11071321 
500 |a 2076-3921 
520 |a Recent studies have revealed that hydrogen sulfide (H<sub>2</sub>S) increases the analgesic actions of the δ-opioid receptor (DOR) in inflammatory pain. However, the possible improvement of the analgesia of μ-opioid receptor (MOR) and DOR agonists during neuropathic pain, through pretreatment with two slow-releasing H<sub>2</sub>S donors-DADS (diallyl disulfide) and GYY4137 (morpholin-4-ium 4-methoxyphenyl(morpholino) phosphinodithioate dichloromethane complex)-is still unknown. In male C57BL/6J mice with neuropathic pain incited by chronic constriction of the sciatic nerve (CCI), we evaluated: (1) the influence of DADS (3.5 mg/kg) and GYY4137 (0.7 mg/kg) on the inhibition of the allodynia and hyperalgesia produced by the systemic or local administration of morphine (3 mg/kg or 65 µg) and UFP-512 (1 mg/kg or 12.5 µg); (2) the reversion of the antinociceptive actions of high doses of DADS (30 mg/kg) and GYY4137 (24 mg/kg) with MOR and DOR antagonists; and (3) the effects of H<sub>2</sub>S donors on oxidative stress, apoptotic responses, and MOR and DOR expression in the medial septum (MS) and dorsal root ganglia (DRG). The results revealed that both DADS and GYY4137 improved the antiallodynic effects of morphine and UFP-512, possibly by up-regulating MOR and DOR expression in DRG. The administration of MOR and DOR antagonists blocked the analgesic properties of DADS and GYY4137, revealing the feasible participation of the endogenous opioid system in H<sub>2</sub>S analgesic effects. Moreover, both H<sub>2</sub>S donors inhibited oxidative stress and apoptosis generated by CCI in the MS and/or DRG. This study suggests the co-treatment of H<sub>2</sub>S donors with MOR or DOR agonists as a potential therapy for neuropathic pain. 
546 |a EN 
690 |a analgesia 
690 |a apoptosis 
690 |a hydrogen sulfide 
690 |a neuropathic pain 
690 |a opioids 
690 |a oxidative stress 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antioxidants, Vol 11, Iss 7, p 1321 (2022) 
787 0 |n https://www.mdpi.com/2076-3921/11/7/1321 
787 0 |n https://doaj.org/toc/2076-3921 
856 4 1 |u https://doaj.org/article/0cf3b559750a4dbd9f62b0f5a8bcf93f  |z Connect to this object online.